Icon this week announced that it has acquired Symphony Clinical Research for an undisclosed amount.

The deal was finished in late September and complements Icon’s PMG Research and MeDiNova Research site networks in the U.S., Europe, Middle East and Africa.

Symphony’s acquisition will help reduce travel burden for patients by giving them access to clinical research studies that they have otherwise not been able to participate in.

“As the pioneer in alternate-site services, Symphony integrates clinical trial expertise with project management; in-home care and nursing to bring the site visit to the patient wherever the live. Icon provides Symphony with a great opportunity to extend our services globally and to use our knowledge, infrastructures and network to support Icon to enhance patient recruitment, engagement and retention,” Symphony Clinical Research CEO Nicki Norris said in a news release.

“Icon has a focused patient, site and data strategy which is helping us to improve site identification, study placement, patient recruitment and retention,” CEO of Icon Steve Cutler said. “A core objective of our patient-centered approach is to increase predictability in patient recruitment and improve patient engagement. Symphony Clinical Research further enhances this approach by providing us with the capability to offer patients at-home trial services making clinical trials more accessible for patients and improving enrollment. Symphony’s clinical trial experience and their strong therapeutic expertise will also enable us to broaden our hybrid solutions to customers and support services to sites.”